Arch Biopartners Inc. (ACHFF)
- Previous Close
1.2500 - Open
1.2800 - Bid --
- Ask --
- Day's Range
1.2500 - 1.2860 - 52 Week Range
0.7200 - 1.8800 - Volume
3,788 - Avg. Volume
23,644 - Market Cap (intraday)
78.57M - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 28, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada.
www.archbiopartners.comRecent News: ACHFF
Performance Overview: ACHFF
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACHFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACHFF
Valuation Measures
Market Cap
78.56M
Enterprise Value
82.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-105.69%
Return on Assets (ttm)
-133.37%
Return on Equity (ttm)
--
Revenue (ttm)
1.85M
Net Income Avi to Common (ttm)
-1.95M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
302.63k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
180.99k
Research Analysis: ACHFF
Company Insights: ACHFF
ACHFF does not have Company Insights